glaucoma Archives -

Nicox has had both good and bad news from a much-anticipated phase 3 trial of its glaucoma therapy

Nicox glaucoma drug works, but not as well as hoped

https://pharmaphorum.com/news/nicox-glaucoma-drug-works-but-not-as-well-as-hoped/

Oculis SA and EBAC join to drive ophthalmology innovation

Nicole Raleigh biopharma, business, EBAC, eye disease, eye drops, glaucoma, Oculis, ophthalmology, research and development, topical treatment 0 Comment

Oculis SA, a global biopharmaceutical company that develops treatments for saving sight and improving eye care with breakthrough

Oculis SA and EBAC join to drive ophthalmology innovation

https://pharmaphorum.com/news/oculis-sa-and-ebac-join-to-drive-ophthalmology-innovation/

News/ News/ Sales and Marketing

Alcon eyes $770m takeover of ophthalmology specialist Aerie

Phil Taylor aerie pharmaceuticals, Alcon, glaucoma, M&A, ophthalmology 0 Comment

Swiss eyecare firm Alcon has made a move to boost its position in ophthalmological medicines with a $15.25

Alcon eyes $770m takeover of ophthalmology specialist Aerie

https://pharmaphorum.com/news/alcon-eyes-770m-takeover-of-ophthalmology-specialist-aerie/

Events/ Events/ Oncology

New Horizon for Treatment of Inherited Retinal Dystrophy

Pavan Solanki glaucoma, Oncology, pharma, retinal dystrophy, voretigene 0 Comment

Latest developments and innovations in ocular gene edit

New Horizon for Treatment of Inherited Retinal Dystrophy

https://pharmaphorum.com/events/new-horizon-for-treatment-of-inherited-retinal-dystrophy/

Partner content/ Partner Content/ Press releases

Queen’s University Belfast and Santen to Present Opening Keynote this November

Pavan Solanki gene editing, gene therapy, glaucoma, ophthalmology, santen 0 Comment

Ophthalmic Drugs Conference London

Queen’s University Belfast and Santen to Present Opening Keynote this November

https://pharmaphorum.com/partner-content/queens-university-belfast-and-santen-to-present-opening-keynote-this-november/

Market Access/ News/ News

Astellas buys eye gene therapy biotech Quethera for $109m

Piotr Wnuk Astellas, gene therapy, glaucoma, ocular disorders, ophthalmology, Quethera 0 Comment

Japanese Astellas Pharma has bought privately-owned biotech Quethera for $109 million, gaining access to its gene therapy focused

Astellas buys eye gene therapy biotech Quethera for $109m

https://pharmaphorum.com/news/astellas-expands-ocular-gene-therapy-investment/

Events/ Events/ R&D

Ophthalmic Drugs 2018

Pavan Solanki glaucoma, NHS, ophthalmic, ophthalmology, retina 0 Comment

Ophthalmic Drugs Conference 2018

Ophthalmic Drugs 2018

https://pharmaphorum.com/events/ophthalmic-drugs-2018/

Healthcare/ Partner content/ Press releases

SMi’s Europe’s Leading Ophthalmic Conference is only 3 weeks away!

Pavan Solanki glaucoma, lentivector, ophthalmic, preclinical, vision 0 Comment

Europe’s Leading Ophthalmic Conference

SMi’s Europe’s Leading Ophthalmic Conference is only 3 weeks away!

https://pharmaphorum.com/partner-content/smis-europes-leading-ophthalmic-conference-is-only-3-weeks-away/

Healthcare/ Partner content/ Press releases

Spotlight on Key Sessions at Ophthalmic Drugs this November

Pavan Solanki drugs, glaucoma, ophthalmic, ophthalmology, technologies

Sessions at Ophthalmic Drugs

Spotlight on Key Sessions at Ophthalmic Drugs this November

https://pharmaphorum.com/partner-content/spotlight-on-key-sessions-at-ophthalmic-drugs-this-november/

Trending

glaucoma

Login